CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome

Takashi Kanbayashi, Tohru Kodama, Hideaki Kondo, Shinsuke Satoh, Yuichi Inoue, Shigeru Chiba, Tetsuo Shimizu, Seiji Nishino

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Study Objective: To (1) replicate our prior result of low cerebrospinal fluid (CSF) histamine levels in human narcolepsy in a different sample population and to (2) evaluate if histamine contents are altered in other types of hypersomnia with and without hypocretin deficiency. Design: Cross sectional studies. Setting and Patients: Sixty-seven narcolepsy subjects, 26 idiopathic hypersomnia (IHS) subjects, 16 obstructive sleep apnea syndrome (OSAS) subjects, and 73 neurological controls were included. All patients were Japanese. Diagnoses were made according to ICSD-2. Results: We found significant reductions in CSF histamine levels in hypocretin deficient narcolepsy with cataplexy (mean ± SEM; 176.0 ± 25.8 pg/mL), hypocretin non-deficient narcolepsy with cataplexy (97.8 ± 38.4 pg/mL), hypocretin non-deficient narcolepsy without cataplexy (113.6 ± 16.4 pg/mL), and idiopathic hypersomnia (161.0 ± 29.3 pg/ mL); the levels in OSAS (259.3 ± 46.6 pg/mL) did not statistically differ from those in the controls (333.8 ± 22.0 pg/mL). Low CSF histamine levels were mostly observed in non-medicated patients; significant reductions in histamine levels were evident in non-medicated patients with hypocretin deficient narcolepsy with cataplexy (112.1 ± 16.3 pg/ mL) and idiopathic hypersomnia (143.3 ± 28.8 pg/mL), while the levels in the medicated patients were in the normal range. Conclusion: The study confirmed reduced CSF histamine levels in hypocretin-deficient narcolepsy with cataplexy. Similar degrees of reduction were also observed in hypocretin non-deficient narcolepsy and in idiopathic hypersomnia, while those in OSAS (non central nervous system hypersomnia) were not altered. The decrease in histamine in these subjects were more specifically observed in non-medicated subjects, suggesting CSF histamine is a biomarker reflecting the degree of hypersomnia of central origin.

Original languageEnglish
Pages (from-to)181-187
Number of pages7
JournalSleep
Volume32
Issue number2
DOIs
Publication statusPublished - 2009

Fingerprint

Idiopathic Hypersomnolence
Narcolepsy
Obstructive Sleep Apnea
Histamine
Cataplexy
Cerebrospinal Fluid
Disorders of Excessive Somnolence
Orexins
Reference Values
Central Nervous System
Cross-Sectional Studies
Biomarkers

All Science Journal Classification (ASJC) codes

  • Clinical Neurology
  • Physiology (medical)

Cite this

Kanbayashi, T., Kodama, T., Kondo, H., Satoh, S., Inoue, Y., Chiba, S., ... Nishino, S. (2009). CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome. Sleep, 32(2), 181-187. https://doi.org/10.1093/sleep/32.2.181

CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome. / Kanbayashi, Takashi; Kodama, Tohru; Kondo, Hideaki; Satoh, Shinsuke; Inoue, Yuichi; Chiba, Shigeru; Shimizu, Tetsuo; Nishino, Seiji.

In: Sleep, Vol. 32, No. 2, 2009, p. 181-187.

Research output: Contribution to journalArticle

Kanbayashi, T, Kodama, T, Kondo, H, Satoh, S, Inoue, Y, Chiba, S, Shimizu, T & Nishino, S 2009, 'CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome', Sleep, vol. 32, no. 2, pp. 181-187. https://doi.org/10.1093/sleep/32.2.181
Kanbayashi, Takashi ; Kodama, Tohru ; Kondo, Hideaki ; Satoh, Shinsuke ; Inoue, Yuichi ; Chiba, Shigeru ; Shimizu, Tetsuo ; Nishino, Seiji. / CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome. In: Sleep. 2009 ; Vol. 32, No. 2. pp. 181-187.
@article{d6902973cf694974b32a881c8cd5d41c,
title = "CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome",
abstract = "Study Objective: To (1) replicate our prior result of low cerebrospinal fluid (CSF) histamine levels in human narcolepsy in a different sample population and to (2) evaluate if histamine contents are altered in other types of hypersomnia with and without hypocretin deficiency. Design: Cross sectional studies. Setting and Patients: Sixty-seven narcolepsy subjects, 26 idiopathic hypersomnia (IHS) subjects, 16 obstructive sleep apnea syndrome (OSAS) subjects, and 73 neurological controls were included. All patients were Japanese. Diagnoses were made according to ICSD-2. Results: We found significant reductions in CSF histamine levels in hypocretin deficient narcolepsy with cataplexy (mean ± SEM; 176.0 ± 25.8 pg/mL), hypocretin non-deficient narcolepsy with cataplexy (97.8 ± 38.4 pg/mL), hypocretin non-deficient narcolepsy without cataplexy (113.6 ± 16.4 pg/mL), and idiopathic hypersomnia (161.0 ± 29.3 pg/ mL); the levels in OSAS (259.3 ± 46.6 pg/mL) did not statistically differ from those in the controls (333.8 ± 22.0 pg/mL). Low CSF histamine levels were mostly observed in non-medicated patients; significant reductions in histamine levels were evident in non-medicated patients with hypocretin deficient narcolepsy with cataplexy (112.1 ± 16.3 pg/ mL) and idiopathic hypersomnia (143.3 ± 28.8 pg/mL), while the levels in the medicated patients were in the normal range. Conclusion: The study confirmed reduced CSF histamine levels in hypocretin-deficient narcolepsy with cataplexy. Similar degrees of reduction were also observed in hypocretin non-deficient narcolepsy and in idiopathic hypersomnia, while those in OSAS (non central nervous system hypersomnia) were not altered. The decrease in histamine in these subjects were more specifically observed in non-medicated subjects, suggesting CSF histamine is a biomarker reflecting the degree of hypersomnia of central origin.",
author = "Takashi Kanbayashi and Tohru Kodama and Hideaki Kondo and Shinsuke Satoh and Yuichi Inoue and Shigeru Chiba and Tetsuo Shimizu and Seiji Nishino",
year = "2009",
doi = "10.1093/sleep/32.2.181",
language = "English",
volume = "32",
pages = "181--187",
journal = "Sleep",
issn = "0161-8105",
publisher = "American Academy of Sleep Medicine",
number = "2",

}

TY - JOUR

T1 - CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome

AU - Kanbayashi, Takashi

AU - Kodama, Tohru

AU - Kondo, Hideaki

AU - Satoh, Shinsuke

AU - Inoue, Yuichi

AU - Chiba, Shigeru

AU - Shimizu, Tetsuo

AU - Nishino, Seiji

PY - 2009

Y1 - 2009

N2 - Study Objective: To (1) replicate our prior result of low cerebrospinal fluid (CSF) histamine levels in human narcolepsy in a different sample population and to (2) evaluate if histamine contents are altered in other types of hypersomnia with and without hypocretin deficiency. Design: Cross sectional studies. Setting and Patients: Sixty-seven narcolepsy subjects, 26 idiopathic hypersomnia (IHS) subjects, 16 obstructive sleep apnea syndrome (OSAS) subjects, and 73 neurological controls were included. All patients were Japanese. Diagnoses were made according to ICSD-2. Results: We found significant reductions in CSF histamine levels in hypocretin deficient narcolepsy with cataplexy (mean ± SEM; 176.0 ± 25.8 pg/mL), hypocretin non-deficient narcolepsy with cataplexy (97.8 ± 38.4 pg/mL), hypocretin non-deficient narcolepsy without cataplexy (113.6 ± 16.4 pg/mL), and idiopathic hypersomnia (161.0 ± 29.3 pg/ mL); the levels in OSAS (259.3 ± 46.6 pg/mL) did not statistically differ from those in the controls (333.8 ± 22.0 pg/mL). Low CSF histamine levels were mostly observed in non-medicated patients; significant reductions in histamine levels were evident in non-medicated patients with hypocretin deficient narcolepsy with cataplexy (112.1 ± 16.3 pg/ mL) and idiopathic hypersomnia (143.3 ± 28.8 pg/mL), while the levels in the medicated patients were in the normal range. Conclusion: The study confirmed reduced CSF histamine levels in hypocretin-deficient narcolepsy with cataplexy. Similar degrees of reduction were also observed in hypocretin non-deficient narcolepsy and in idiopathic hypersomnia, while those in OSAS (non central nervous system hypersomnia) were not altered. The decrease in histamine in these subjects were more specifically observed in non-medicated subjects, suggesting CSF histamine is a biomarker reflecting the degree of hypersomnia of central origin.

AB - Study Objective: To (1) replicate our prior result of low cerebrospinal fluid (CSF) histamine levels in human narcolepsy in a different sample population and to (2) evaluate if histamine contents are altered in other types of hypersomnia with and without hypocretin deficiency. Design: Cross sectional studies. Setting and Patients: Sixty-seven narcolepsy subjects, 26 idiopathic hypersomnia (IHS) subjects, 16 obstructive sleep apnea syndrome (OSAS) subjects, and 73 neurological controls were included. All patients were Japanese. Diagnoses were made according to ICSD-2. Results: We found significant reductions in CSF histamine levels in hypocretin deficient narcolepsy with cataplexy (mean ± SEM; 176.0 ± 25.8 pg/mL), hypocretin non-deficient narcolepsy with cataplexy (97.8 ± 38.4 pg/mL), hypocretin non-deficient narcolepsy without cataplexy (113.6 ± 16.4 pg/mL), and idiopathic hypersomnia (161.0 ± 29.3 pg/ mL); the levels in OSAS (259.3 ± 46.6 pg/mL) did not statistically differ from those in the controls (333.8 ± 22.0 pg/mL). Low CSF histamine levels were mostly observed in non-medicated patients; significant reductions in histamine levels were evident in non-medicated patients with hypocretin deficient narcolepsy with cataplexy (112.1 ± 16.3 pg/ mL) and idiopathic hypersomnia (143.3 ± 28.8 pg/mL), while the levels in the medicated patients were in the normal range. Conclusion: The study confirmed reduced CSF histamine levels in hypocretin-deficient narcolepsy with cataplexy. Similar degrees of reduction were also observed in hypocretin non-deficient narcolepsy and in idiopathic hypersomnia, while those in OSAS (non central nervous system hypersomnia) were not altered. The decrease in histamine in these subjects were more specifically observed in non-medicated subjects, suggesting CSF histamine is a biomarker reflecting the degree of hypersomnia of central origin.

UR - http://www.scopus.com/inward/record.url?scp=62549089695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62549089695&partnerID=8YFLogxK

U2 - 10.1093/sleep/32.2.181

DO - 10.1093/sleep/32.2.181

M3 - Article

C2 - 19238805

AN - SCOPUS:62549089695

VL - 32

SP - 181

EP - 187

JO - Sleep

JF - Sleep

SN - 0161-8105

IS - 2

ER -